Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionCapitolis Liquid Global Markets LLC
Latest Disclosed Ownership80,000 shares
Latest Disclosed Value $ 61,749,600
Capitolis Liquid Global Markets LLC reports 6.67% increase in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On February 17, 2026 - Capitolis Liquid Global Markets LLC filed a 13F-HR form disclosing ownership of 80,000 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $61,749,600 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 14, 2025 disclosing 75,000 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of 6.67% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-17 2025-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 80,000 5,000 6.67 61,750 46.43 0.3683
2025-11-14 2025-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 75,000 -93,000 -55.36 42,170 -52.19 0.3368
2025-08-14 2025-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 168,000 117,000 229.41 88,200 172.69 0.6461
2025-05-15 2025-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 51,000 -36,000 -41.38 32,346 -47.81 0.2859
2025-02-14 2024-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 87,000 49,000 128.95 61,973 55.14 0.6036
2024-11-14 2024-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 38,000 0 0.00 39,947 0.02 0.4238
2024-08-13 2024-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 38,000 0 0.00 39,939 9.20 0.4938
2024-05-13 2024-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 38,000 38,000 36,575 0.5866
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.